September 8, 2017

September 08, 2017

Peregrine Pharmaceuticals Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma
Clinical Leader – Sept. 7
“We look forward to following this important study at the Massachusetts General Hospital Cancer Center, as well as the planned trials at the Moffitt Cancer Center and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.”                   

Gardasil 9 efficacious in preventing HPV
Healio – Sept. 7
“Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90% of cervical cancer, 90% of HPV-related vulvar and vaginal cancer, 70 to 85% of high-grade cervical disease in females, and approximately 90% of HPV-related anal cancer and genital warts in males and females worldwide,” Anna R. Giuliano, PhD, director of the Center for Infection Research in Cancer at Moffitt Cancer Center, said in a press release. Also seen on NewsMedical and European Pharmaceutical Review.

Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL
OncLive – Sept. 7
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

Triple-Negative Breast Cancer Treatment Market New Study Offers Insights for 2017 – 2025
Digital Journal – Sept. 7

According to the research article published in Journal of the Moffitt Cancer Center, around 1 million breast cancers are diagnosed globally among them 1.7% of cancer cases are triple-negative cancers. 

Hillsborough Society Datebook 2017-18
Tampa Bay Times – Sept. 7
April 14: Magnolia Ball benefits Moffitt Cancer Center; 6 p.m.; Marriott Waterside; $1,500 and up; black-tie; (813) 745-4860 or

Moffitt cancer center trying to partner with researchers in Cuba
Tampa Bay Times – Sept. 7
For the last 18 months, cooperation has occurred below the radar for Tampa's H. Lee Moffitt Cancer Center & Research Institute and two centers in Cuba — the National Institute of Oncology and Radiobiology and the Center of Molecular Immunology.

Completion lymph node dissection ‘not yet obsolete’
Healio – Sept. 7
By Vernon K. Sondak, MD: The surgical management of the regional lymph nodes in melanoma has long been an area of controversy.

Study finds improved vaccine that protects against nine types of HPV
Infection Control Today – Sept. 6
The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease. The study was published this week in The Lancet.

New vaccine protects against nine types of HPV
UPI – Sept. 6
Researchers at the H. Lee Moffitt Cancer Center & Research Institute found that an improved vaccine is able to protect against nine types of HPV.

Unmet Needs in CINV
OncLive – Sept. 6
Dawn Dolan, PharmD, BCOP: We try to be as aggressive as possible in those particular patients. Like you had said before, these are curable patients. We do not need them falling off the wagon or coming back to us saying they don’t want therapy. We need to get them through, and we need to be aggressive, up front.

How a cancer research and treatment center used hybrid cloud to modernize its data center
TechRepublic – Sept. 6
Tom Hull, Moffitt Cancer Center CTO, describes how using the hybrid cloud has improved the company's security and balanced workload.

Tampa Bay Times – Sept. 6
Martinis for Moffitt, begun 10 years ago to fund prostate cancer research, topped 1,200 guests this year.

Martin Health For You: Mindfulness yoga for cancer
Palm Beach Post – Sept. 5
After attending a Mindfulness Yoga and Meditation for Cancer Care Workshop last year in Tampa, I was inspired to introduce this powerful program to Martin Health and the Treasure Coast community. This program is an integral component of the Moffitt Center’s support for cancer patients and survivors.

Bull of the Day: Jazz Pharmaceuticals (JAZZ)
Nasdaq – Sept. 5
"Vyxeos is the first chemotherapy to demonstrate an overall survival advantage over the standard of care in a Phase 3 randomized study of older adults with newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes," said Jeffrey E. Lancet, MD, Chair of the Department of Malignant Hematology at Moffitt Cancer Center.

New Lung Cancer Screening Model Could Identify High Risk Patients Earlier
PressPoint Release – Sept. 5
Early detection is key when it comes to lung cancer, but a problem physicians face is identifying which patients with small lung nodules are at a greater risk of eventually developing the disease. Moffitt Cancer Center researchers have made significant progress towards a solution.

Triple-Negative Breast Cancer Treatment Market Forecast and Segments 2017 – 2025
MedGadget – Sept. 4
According to the research article published in Journal of the Moffitt Cancer Center, around 1 million breast cancers are diagnosed globally among them 1.7% of cancer cases are triple-negative cancers. 

Cancer Therapy Dog
Bay News 9 – Sept. 4
The pet therapy program has been at Moffitt for nearly 30 years and there are 15 dogs in the program, all certified for pet therapy.

Prostate Cancer Foundation announces Challenge Awards
Healio – Sept. 1
Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer — Nupam Mahajan, PhD, of H. Lee Moffitt Cancer Center, and Felix Feng, MD, of University of California, San Francisco.

HPV e câncer masculine
Drauzio – Sept. 1Três deles, publicados entre 2015 e 2017, trazem uma análise mais detalhada da história natural da infecção por HPV. Em dois papers, o grupo da epidemiologista Anna Giuliano, do Moffitt Cancer Center, na Flórida, coordenadora geral do HIM, relata os resultados da avaliação de cerca de 3 mil desses homens.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.